within Pharmacolibrary.Drugs.ATC.S;

model S01ED05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 0.006333333333333333,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0046,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02666666666666667,
    Tlag           = 0
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01ED05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Carteolol is a non-selective beta-adrenergic blocker primarily used as an ophthalmic solution to reduce intraocular pressure in the treatment of glaucoma and ocular hypertension. It is generally approved and used today in several countries in the form of eye drops.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for carteolol after oral administration in healthy adult volunteers.</p><h4>References</h4><ol><li><p>Ishizaki, T, et al., &amp; Suganuma, T (1983). Pharmacokinetics and absolute bioavailability of carteolol, a new beta-adrenergic receptor blocking agent. <i>European journal of clinical pharmacology</i> 25(1) 95–101. DOI:<a href=&quot;https://doi.org/10.1007/BF00544023&quot;>10.1007/BF00544023</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6137389/&quot;>https://pubmed.ncbi.nlm.nih.gov/6137389</a></p></li><li><p>Hasenfuss, G, et al., &amp; Just, H (1985). Pharmacokinetics of carteolol in relation to renal function. <i>European journal of clinical pharmacology</i> 29(4) 461–465. DOI:<a href=&quot;https://doi.org/10.1007/BF00613462&quot;>10.1007/BF00613462</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/4092726/&quot;>https://pubmed.ncbi.nlm.nih.gov/4092726</a></p></li><li><p>Morita, S, et al., &amp; Kori, H (1977). [Metabolic fate of carteolol hydrochloride (OPC-1085), a new beta-adrenergic blocking agent. (6) Pharmacokinetics of carteolol in the rat, dog, rabbit and man]. <i>Nihon yakurigaku zasshi. Folia pharmacologica Japonica</i> 73(2) 229–235. DOI:<a href=&quot;https://doi.org/10.1254/fpj.73.229&quot;>10.1254/fpj.73.229</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/328355/&quot;>https://pubmed.ncbi.nlm.nih.gov/328355</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01ED05;
